Helius Medical Technologies, Inc. (NASDAQ:HSDT) Sees Significant Decrease in Short Interest

Helius Medical Technologies, Inc. (NASDAQ:HSDT) was the target of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 89,800 shares, a decline of 5.5% from the November 15th total of 95,000 shares. Based on an average trading volume of 361,500 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analyst Weigh In

Separately, Maxim Group reaffirmed a “hold” rating on shares of Helius Medical Technologies in a report on Wednesday, October 16th.

Institutional Investors Weigh In On Helius Medical Technologies

An institutional investor recently bought a new position in Helius Medical Technologies stock. Armistice Capital LLC acquired a new stake in Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 130,000 shares of the company’s stock, valued at approximately $127,000. Armistice Capital LLC owned 4.39% of Helius Medical Technologies as of its most recent SEC filing. Institutional investors own 18.63% of the company’s stock.

Helius Medical Technologies Trading Down 2.1 %

Helius Medical Technologies stock opened at $0.47 on Wednesday. The stock has a 50 day moving average of $0.52 and a two-hundred day moving average of $0.73. Helius Medical Technologies has a twelve month low of $0.37 and a twelve month high of $9.50. The stock has a market capitalization of $1.75 million, a price-to-earnings ratio of -0.08 and a beta of 1.68.

About Helius Medical Technologies

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.